关键词: COVID-19 heparin hydroxychloroquine and azithromycin infectious diseases kidney and liver transplantation nonpathogen-specifc immune parameters

Mesh : Aged Antiviral Agents / therapeutic use Brazil COVID-19 / diagnosis drug therapy immunology virology COVID-19 Nucleic Acid Testing Graft Rejection / immunology prevention & control Humans Immunocompromised Host Immunosuppressive Agents / adverse effects Kidney Failure, Chronic / immunology surgery Kidney Transplantation / adverse effects Lung / diagnostic imaging Male RNA, Viral / isolation & purification SARS-CoV-2 / genetics immunology isolation & purification Tomography, X-Ray Computed Transplant Recipients Treatment Outcome

来  源:   DOI:10.1111/tid.13306   PDF(Sci-hub)   PDF(Pubmed)

Abstract:
In late December 2019, China reported cases of respiratory illness in humans that involved a novel coronavirus SARS-CoV-2. On March 20, 2020, the first coronavirus disease 2019 (COVID-19) in Brazil was diagnosed, and by now, we present the report on the first case of COVID among transplant recipients in our country. A liver and kidney transplant patient with SARS-CoV-2 pneumonia without respiratory failure was treated in a clinical multimodal strategy consisting of symptomatic support therapy, immunosuppression reduction, use of anti-coronavirus drugs and heparin leading to a progressive improvement of patient symptoms till discharge. The authors also present a comprehensive review of published cases.
摘要:
暂无翻译
公众号